New York — Moderna has said it has selected a dose for a final-stage clinical trial of its coronavirus vaccine that should begin in July, as the company moves ahead rapidly with its innovative approach to trying to prevent Covid-19.

The final study, which will include 30,000 people, will be conducted in collaboration with the National Institute of Allergy and Infectious Diseases in the US. Its primary goal will be to show the vaccine prevents people from developing symptoms of Covid-19, Moderna said in a statement. A secondary goal will be to show the vaccine keeps people from getting severe cases that require hospitalisation...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.



Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now